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The accumulation of polymorphonuclear leukocytes 
(PMN) beneath the stratum corneum is a character-
istic histopathologic finding in various aseptic pustu-
lar dermatoses. To elucidate the pathomechanism 
involved in this phenomenon, we investigated 
whether PMN also attach to a sheet of corneocytes in 
vitro. A I_cm2 corneocyte sheet was attached to a 
sterile glass slide with double adhesive tape used for 
skin graft surgery before incubating with human 
serum. The PMN suspension then was applied t o the 
sheet. Attached cells were stained with May-Grun-
wald-Giemsa and counted with a computer image 
analyzer. We quantitatively assessed PMN adhesion 
to the serum-treated corneocyte sheets, which was 
mediated by activation of th e alternative comple-
ment pathway. Addition of either ant i-CDl8 or anti-
e DIIb antibody to the assay syst em resulted in a 
he accumulation of polymorphonuclear leukocytes 
(PMN) on the surface of the stratum corneum is a 
characteristic feature in sterile pustular dermatoses, 
including acutely exacerbating psoriasis vulgaris, 
pustular psoriasis, palmo-plantar pustulosis, and sub-
corneal pustular dermatosis, as well as in acne and ruptured 
epidermal cysts. Binding ofPMN to the stratum corneum occurs in 
these lesions. C5a anaphylatoxin [1], interleukin- 8 [2], leukotriene 
B 4 [3], and platelet-activating factor [4] have been implicated in the 
pathomechanism of PMN migration to corneocytes, although it is 
still not conclusive which factor is most responsible for the PMN 
accumulation. In our previous studies, we demonstrated that 
keratinous materials, such as those obtained from plantar callus and 
contents of epidermal cysts, in the presence of fresh serum in vitro 
can activate the alternative complement pathway to produce CSa 
anaphylatoxin [5,6]. 
It is well known that upon activation of either the classic or the 
alternative complement pathway, the third component of comple-
ment (C3) is bound covalently to the cell surface as C3b, which 
serves as the ligand for the type 1 complement receptor (CR1) on 
PMN. C3 b undergoes further proteolytic cleavage by factor I or 
other enzymes [7] to the relatively stable iC3b opsonin. There is 
accumulating evidence that the leukocyte adhesion molecule family 
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marked reduction ofPMN adhesion. We also demon-
strated immunohistochemically that iC3b was 
formed on the serum-treated corneocytes. These 
findings suggest that PMN attach to serum-treated 
corneocytes through an interaction of CR3 expressed 
on PMN w ith iC3b-coated corneocytes. In addition, 
we found that this adhesion was enhanced by activa-
tion of PMN w ith phorbol myristate acetate. From 
these r esults, we speculate that complement activa-
tion by corneocytes occurs in the cutaneous lesions of 
aseptic pustular dermatoses and that PMN can b e 
stimulat ed by the interaction with iC3b-opsonized 
corneocytes as well as by chemotaxins, leading t o 
damage of the surrounding epidermal keratinocytes. 
K ey words: stratum corneum, PMN, CR3, iC3b, P.MA. 
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CD11/CD18 ({32 integrins) is critical to the function of PMN in 
inflammation and tissue injury [8 -13]. The type-3 complement 
receptor (CR3 or Mac- 1: CDllb/CD18) functions as an opsonic 
receptor, promoting the binding and uptake of iC3b-derivatized 
particles and cells [7]. 
Based on these observations, we can assume that corneocytes 
exposed to the tissue fluid containing complement components are 
coated with the surface-bound fragments of C3 through comple-
ment activation by the corneocytes themselves. In this study, we 
examined potential PMN-corneocyte adhesion mechanisms in vitro. 
MA TERlALS AND METHODS 
Chemicals and Reagents Polymyxin B sulfate, phorbol myristate ace-
tate (PMA), and bovine serum albumin (BSA) were purchased from Sigma 
(St. Louis, MO). Dulbecco's phosphate-buffered saline (PBS) was prepared 
by using water obtained with the Milli-Q reagent water system Oapan 
Millipore, Tokyo, Japan). Mouse IgG1, an isotype control, and mouse IgG1 
monoclonal antibodies 03.D3 , 25.3.1, and M1I17) specific for human CR1 
(CD3S) , leukocyte function antigen-1 (LFA-1) (CD11a), and CR3 
(CDllb) , respectively, were purchased from Chemical International Inc . 
(El Segundo, CA) . Mouse IgG1 monoclonal antibody (MHM23) against 
human CD18 and mouse monoclonal antibody against human iC3b neo-
antigen were obtained from Dakopatts (Denmark) and Quidel (San Diego, 
CA) , respectively. Factor-B-depleted and C1q-depleted sera also were 
obtained from Quidel. Both sera were prepared by imrnunoaffinity chro-
matography from ethylenediamine tetraacetic acid-treated normal human 
serum and reconstituted with divalent cations. Both have been tested to be 
appropriately depleted and have been functionally proven by hemolytic 
assays using rabbit erythrocytes to allow each counter pathway of the 
complement to work appropriately (personal communication from Dr. 
Tamerius, PhD, Quidel). In some experiments, complement was inacti-
vated by heat at 56°C for 30 min; we have found that very small amounts 
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ofC5a and C5a des arg were produced by the incubation of heat-inactivated 
serum with keratinous materials or bacteria [6]. 
Preparation ofPMN Fresh heparinized (20 IV/ml) venous blood from 
healthy donors was mixed with an equal volume of PBS and overlaid 
carefully on 3 ml of Ficoll-Isopaque solution. Mter centrifugation at 300 X 
g for 30 min at room temperature, a PMN-rich fraction was obtained from 
the buffy coat. Contaminating erythrocytes were lysed by a hypotonic 
procedure using 0.2% and 1.8% sodium chloride. PMN were suspended in 
PBS containing 1 % BSA and 40 /-LM of polymyxin B sulfate to negate the 
effects of any endotoxin at a density of 1 X 106 cells/ml. According to this 
method, 94.5 :±: 5.9% of the total obtained cells were neutrophils, and cell 
viability was greater than 95% when examined by the trypan blue exclusion 
method. 
Preparation of Corneocyte Sheets Corneocyte samples were obtained 
from the flexor surface of the forearm of healthy individuals . Double 
adhesive tape used for skin graft surgery (Dermatome Tape, 3M Health 
Care Limited, Tokyo, Japan) was cut into 1 cm X 1 cm pieces and attached 
to a sterile glass slide. A sheet of corneocytes was obtained by pressing the 
tape-attached slide directly onto the skin several times . To prevent nonspe-
cific binding of human PMN to the corneocyte sheet, the sheet was washed 
with PBS containing 1 % BSA, to which 40 /-LM of polymyxin B sulfate was 
added to negate the effects of any endotoxin present, and was subsequently 
incubated with human nontreated or treated serum as indicated in each 
experiment. After three washes with PBS containing 1 % BSA to remove 
soluble factors, the sheet was used for the PMN adhesion study. Our 
preliminary experiment showed that the location in the stratum corneum 
from which the corneocyte sheets were obtained (i.e., after five to 35 tape 
strippings) had no serious influence on this adhesion. In the present study, 
we used a sheet of corneocytes obtained after five tape strippings to remove 
superficial corneocytes. 
Counts ofPMN Adhering to the Corneocyte Sheets Fifty microliters 
of PMN suspension at a dose of 1 X 106 cells/ml was applied to the 
serum-treated corneocyte sheets and incubated at 37°C for each indicated 
time period. The corneocyte sheets were washed gently three times in PBS 
containing 1% BSA to remove nonadherent PMN. Mter fixing the samples 
with methanol, adherent PMN were stained with May-Grunwald-Giemsa. 
The samples were image-analyzed using a computer (PCKD 5 51, Nippon 
Electric Co., Tokyo, Japan) and a digitizer (LA-500, Pias Ltd., Osaka, 
Japan) connected to a microscope (Labophoto, Nikon, Tokyo, Japan) to 
determine the number of attached PMN. The images of samples were fed 
into the image digitizer and then degraded to pixels. The gray level at each 
pixel was obtained, and the binary images were prepared by classifying each 
pixel with a gray level above or below a predetermined slice level as black 
or white, respectively. Mter smoothing the obtained binary images, we 
counted the number of black dots as PMN adhering to the corneocyte 
sheets. All experiments were repeated at least three times, and each 
representative result is shown in the tables and figures. 
Immunofluorescence Staining The corneocyte sheets were incubated 
with 50 /-LI of either non treated serum or heat-inactivated serum for an 
indicated period. After washing with PBS containing 1 % BSA, the sheets 
were incubated with 20 /-Lg/ml of murine monoclonal antibody against 
human iC3b neoantigen at 37°C for 20 min in a moist chamber. They were 
then washed in PBS containing 1 % BSA and incubated again with a 1 :40 
dilution of the fluorescein-isothiocyanate-conjugated goat anti-mouse im-
munoglobulin gamma and light chains at 37°C for 20 min. Slides were 
washed in PBS containing 1 % BSA and mounted in PermaFluor. They were 
viewed and photographed with a Nikon Optiphoto microscope. 
RESULTS 
To investigate PMN-corneocyte adhesion mechanisms, we used a 
corneocyte sheet prepared on double adhesive tape, as described in 
Materials and Methods. Interaction between a sheet of corneocytes 
and human serum used as a complement source resulted in a high 
degree of adhesion of unstimulated PMN (Fig 1a). Complement 
inactivation by heat caused a significant decrease in this PMN 
adhesion (Fig 1b), indicating that adhesion is mediated by comple-
ment activation occurring on the corneocytes. This adhesion was 
found in a dose-dependent fashion. Table I shows a representative 
result. Such a dose-related response in attachment also was ob-
served when the corneocytes were incubated with sera obtained 
from five different donors (data not shown). Although adhesive 
tape alone induced a minor level of PMN adhesion, the number of 
the attached PMN was negligible at 10-fold to 1000-fold dilution of 
THE JOURNAL OF INVESTIGATIVE DERMATOLOG 
• .. 
.. 
a • 
Figure 1. PMN attachment to serum-treated corneocyte sheets. a) 
A sheet of corneocytes prepared on adhesive tape was incubated with 
1: 1 O-diluted, nontreated human serum at 37°C for 45 min. Then, 50 /-LI of 
1 X 106 PMN/ml was put on the corneocyte sheet and incubated at 37°C 
for 30 min. Attached cells were stained with Giemsa and counted (see 
Materials and Methods). b) The corneocyte sheet was treated with heat-
inactivated serum and processed as mentioned above. Bar, 30 /-Lm . 
serum (Table I). Thus, in the later experiments, we used 10-fold 
diluted serum samples. 
In Fig 2a,b, the time required for the induction of PMN 
adhesion is demonstrated. First, the corneocyte sheets were incu-
bated with 1: 1 0 diluted serum at 3 rc for each indicated period, as 
shown in Fig 2a. PMN then were applied and the sheets incubated 
at 37°C for 30 min. Adhesion was detected as early as 5 min of 
incubation of corneocytes with the complement source. The adhe-
sion reached a peak at 45 min and later declined gradually. 
Inactivation of complement by heat led to a marked reduction in 
PMN adhesion, although some adhesion occurred after longer 
serum exposure. Second, the corneocyte sheets were treated with 
serum at 37°C for a fixed period, 45 min, and PMN were applied 
to them and incubated for each indicated period, as shown in Fig 
2b. The results indicated that PMN adhesion peaked at 30 min of 
incubation with the already serum-treated comeocytes; there was a 
sluggish decrease in PMN adhesion after additional incubation. We 
found that with an increase in incubation time (longer than 120 
min), a relatively high level of PMN binding occurred to the 
corneocytes, even after treatment with heat-inactivated serum. 
To characterize this phenomenon further, we us~d special sera 
from which only a single component of complement (C1q or factor 
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Table I. Induction of Dose-Dependent PMN Adhesion 
to the Serum-Treated Corneocyte Sheets on Adhesive 
Tape by Complement Activationa 
Corneocytes on 
Adhesive Tape Alone Adhesive Tape 
Serum 
Dilution NTSb HIS' NTS HIS 
1:1 33.8 ± 4.0 7.6 ± 1.2 107.6 ± 9.6 20.4 ± 1.2 
1:10 11.0 ± 0.8 4.0 ± 0.7 55.2 ± 3.5 4.8 ± 0.4 
1:100 6.6 ± 1.1 4.0 ± 0.3 17.6±2.8 4.8 ± 0.4 
1:1000 6.8 ± 1.4 3.4 ± 0.5 3.4 ± 0.5 3.6 ± 0.7 
No serum 2.4 ± 0.4 2.4 ± 0.5 
a A sheet of comeocytes prepared on adhesive tape (see Materials OIld Methods) or 
adhesive tape itself was incubated with serially diluted, nontreated serum at 37°C for 
45 min. Then, 50 ILl of 1 X 106 PMN/rnl was overlaid on it and incubated at 37°C for 
30 min. Attached cells were stained with Giemsa and counted with a computer image 
analyzer. Data are presented as mean ± standard deviation in cells/field. 
" NTS, nontreated serum. 
C HIS, heat-inactivated serum. 
B) was removed, and compared the results to those obtained with 
nontreated serum. As illustrated in Fig 3, factor-B depletion 
resulted in a marked decrease in attached cell number. However, 
removal ofClq did not influence PMN binding significantly, which 
indicates that PMN attach to the corneocytes mainly by activation 
of the alternative complement pathway. 
In the next experiment, we examined the PMN receptors 
responsible for adherence to the serum-treated corneocytes by 
pretreating PMN at 37°C for 20 min with a panel of monoclonal 
antibodies specific for the molecules (CD18, CDlla, CDllb, and 
CD35) of individual receptors. We obtained an unequivocal result 
identifying CR3 as a responsible molecule, as shown in Table II. 
Each antibody (20 J.Lg/ml) to the a- or J3-chain of CR3 (CDllbl 
CD18) strongly inhibited this PMN adhesion to a level that was 
obtained with heat-inactivated serum. None of the antibodies to 
LFA-l a-chain (CDlla) or CRl (CD35), or to mouse IgGl as an 
isotype control, inhibited this adhesion (Table II) even at high 
concentrations up to 180 J.Lg/ml. Further, none of them augmented 
the inhibition mediated by anti-CD 11 b antibody (data not shown). 
To ascertain iC3b deposition on the serum-treated corneocytes, we 
performed an immunohistochemical study. This demonstrated faint 
iC3 b deposition, even after a 5-min incubation of the corneocyte 
sheet with nontreated serum (Fig 4a), shown by an increase in 
fluorescence intensity according to the length of the incubation 
time (30 to 60 min) (Fig 4b,c). In contrast, heat inactivation of 
serum abrogated the iC3 b deposition even after a 60-min incuba-
tion (Fig 4d). 
PMA is known to influence the capacity of PMN to bind and 
uptake iC3b-derivatized particles and cells [14-16]. To examine 
whether PMA affects PMN adhesion to corneocytes, PMN were 
incubated with 30 ng/ml of PM A at 37°C for various time intervals, 
as shown in Fig 5, and their capacity to bind the serum-treated 
corneocytes was determined as described above. The results indi-
cated that unstimulated PMN bound the corneocytes at a level 
comparable to that found in Table I. On the other hand, pre-
treatment ofPMN with PMA for 10 min led to a significant increase 
in PMN adherence (151% of the control). Moreover, addition of 
PMA to the PMN suspension at the beginning of the adherence 
assay also caused a marked enhancement ofPMN binding (183% of 
control). However, upon pre-treatment of PMN with PMA for 
longer than 20 min, PMN adhesion declined sharply and in a 
time-dependent manner. The time course of expression of receptor 
was independent of PMA concentrations from 30 to 100 ng/ml 
(data not shown). 
DISCUSSION 
In this study, we quantitatively assessed PMN adhesion to a 
corneocyte sheet prepared on double adhesive tape. We also 
demonstrated that this adhesion is mediated by activation of the 
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alternative complement pathway. To identify a possible PMN 
receptor for adherence to the corneocytes, we performed inhibition 
assays using monoclonal antibodies specific for human adhesion 
molecules (CD11a, CDllb, CD18, and CD35) expressed on PMN. 
The results showed that the monoclonal antibody against either the 
a- or J3-chain of CR3 (CDllb/CD18) strongly inhibited PMN 
adhesion, whereas anti-CRl (CD35) antibody did not affect this 
adhesion. We also demonstrated immunohistochemically the for-
mation of iC3b on the corneocytes treated with serum. This 
indicates that CR3 expressed on PMN is responsible for the PMN 
binding to corneocytes and that iC3b, the only known complement 
factor to bind CR3 [17], is the corneocyte-bound ligand. 
Recent work has suggested that CR3 also binds fibrinogen [18]. 
Neither heat inactivation of serum nor factor-B depletion by affinity 
column affects fibrinogen. Therefore, because both of these activ-
ities inhibited PMN adhesion significantly, we do not think that 
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Figure 2. Time relation for the induction ofPMN adhesion. a) The 
corneocyte sheets were incubated with 1:10-diluted serum at 37°C for 
indicated periods. PMN then were applied to the sheets and incubated at 
37°C for 30 min. b) PMN were applied to the corneocyte sheets that had 
been treated with 1:10-diluted serum at 37°C for 45 min, and incubated at 
37°C for indicated periods. NTS, nontreated serum; HIS, heat-inactivated 
serum. 
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Figure 3. Activation of the alternative complement pathway plays 
a main role in PMN adhesion to corneocyte sheets. The comeocyte 
sheets were incubated with 1:10-diluted, factor-B-depleted serum or 
Clq-depleted serum. PMN adhesion was compared to that found with 
nontreated serum (NTS) or heat-inactivated serum (HIS). 
fibrinogen plays any pivotal role in this adhesion assay. p150,95 
(CDllc/CD18) is known to be another PMN receptor for iC3b. 
However, this interaction is shown to occur only under unphysio-
logic low-salt conditions [19]. Moreover, PMN have only 5000-
7000 molecules of p1S0,9S, whereas they have about 50,000 
molecules of CRJ [7]. From these facts, it is unlikely that this PMN 
adhesion is mainly mediated by p150,95. 
Resting PMN have a relatively low capacity to bind and phago-
cytose iC3b-opsonized particles. Many agents, including chemo-
taxins such as C5a, N-formyl-methionyl-Ieucyl-phenylalanine 
(FMLP) [14,15,20], and interleukin-8 [21], and secretary agonists 
such as tumor necrosis factor [22] and PMA [14-16], are reported 
to be capable of enhancing CR3 function. Thus, we performed an 
experiment to examine whether pre-treatment with PMA affects 
Table II. CR3 is Responsible for PMN Binding to 
Corneocyte Sheets 
AntibodiesQ 
Serum CD18 CDl1a CDllb CD35 mlgGl PMN Adhesionb 
Exp.l 
NTS' 
HISd 
NTS 
NTS 
Exp.2 
NTS 
HIS 
NTS 
NTS 
NTS 
NTS 
+ 
+ 
+ 
+ 
+ 
+ 
53.1 ± 7.5 
12.0 ± 6.7 
53.6 ± 6.4 
16.5 ± 6.4 
57 .3 ± 6.4 
12.3 ± 2.5 
50.2 ± 3.5 
59.0 ± 10.4 
57.0 ± 13.4 
18.1 ± 8.6 
Q Inhibition assays were carried out by adding each monoclonal antibody (20 J,Lg/ml) 
specific for human CDl8 (common {3-chain of (32 integrins), CDlla (LFA-l a-chain), 
CDllb (CR3 a-chain), or CD35 (CRl) to the adhesion assay system. Mouse IgGl (20 
J,Lg/mI) also was used as an isotype control. Anti-CDl8 and anti-CDllb antibodies 
blocked the PMN binding markedly, whereas neither anti-CD35 (CRt) nor anti-
CDlla (LFA-l a-chain) antibody did so. 
b Data are presented as mean ± standard deviation in cells/field. 
, NTS, l: to-diluted, nontreated serum. 
d HIS, heat-inactivated serum (56°C , 30 min). 
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Figure 4. Immunofluorescence staining using antibody against 
iC3b. The comeocyte sheets were incubated with nontreated serum or 
heat-inactivated serum for an indicated period. The process of iC3b 
formation was followed using a direct immunofluorescence technique (see 
Materials and Methods). a) 5-min incubation with nontreated serum; b) 
30-min incubation with nontreated serum; c) 60-min incubation with 
nontreated serum; d) 60-min incubation with heat-inactivated serum. Bar, 
40 /-Lm. 
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Figure 5. Stimulation ofPMN with PMA influences PMN adhesion 
to serum-treated corneocytes. 30 ng/ml ofPMA was added to the PMN 
suspension at the beginning of the adherence assay, or PMN were pretreated 
with the same concentration of PMA at 37°C for indicated periods. PMN 
were put on the serum-treated corneocyte sheets and incubated at 37°C for 
30 min. 
PMN attachment to comeocytes. The results showed that pre-
treatment of PMN with PMA for 10 min or the addition of PMA at 
the beginning of the adherence assay increased PMN adhesion 
prominently. However, after pre-treatment ofPMN with PMA for 
20 min or more, adhesion declined in a time-dependent manner to 
the level obtained with heat-inactivated serum. Wright and Meyer 
[16] also showed that CR3 function was down-regulated by 
phorbol esters at a time when the surface of CR3 remained 
constant. It is highly likely from our present results that in the 
pathologic conditions noted with aseptic PMN accumulation, che-
moattractants including C5a [5,6] and interleukin-8 [2] exert a 
proinflammatory effect in an early phase to induce subsequent PMN 
adhesion to comeocytes . In contrast, increasing the time of PMN 
exposure to these factors causes a deactivation of accumulated 
PMN, as a regulatory system to avoid excessive insults to the 
surrounding tissue by these stimulated PMN. 
It is known that the ligation of CR3 on PMN promotes 
inflammation and tissue damage [7-13]. Our present findings 
suggest that this ligation occurs through the interaction of CR3 on 
PMN, with iC3b opsonin formed on the comeocytes . We can 
assume that this interaction may cause PMN to be stimulated to 
damage epidermal keratinocytes surrounding the aseptic pustule. 
Based on the results of our present study, we think that blocking 
CR3 in vivo might produce beneficial anti-inflammatory effects 
through the avoidance of both PMN attachment to comeocytes and 
subsequent release of either active oxygen metabolites or enzymes, 
as well as through the inhibition of PMN recruitment to extravas-
cular sites, and that CR3 might be a useful target for anti-
inflammatory drug therapy. 
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